Intrahepatic Cholangiocarcinoma (ICCA)-Epidemiology Forecast–2030

DelveInsight’s ‘Intrahepatic Cholangiocarcinoma (ICCA)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Intrahepatic Cholangiocarcinoma (ICCA) Disease Understanding
Intrahepatic cholangiocarcinoma (ICCA), a primary malignant neoplasm of the liver secondary to hepatocellular carcinoma, arises from the intrahepatic biliary epithelium (lining epithelia and peribiliary glands) and shows a variable cholangiocytic differentiation. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural).

Based on the macroscopic tumor growth pattern ICCA can be classified as mass-forming type, periductal infiltrating type, or intraductal growing type according to the classification of the Liver Cancer Study Group of Japan. It can also be classified into two types according to the site of involvement and histologic features: perihilar large duct ICCA, which involves the intrahepatic large bile ducts, and peripheral small duct ICCA, which involves the intrahepatic small bile ducts

Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of ICCA, Gender-specific Incident Cases of ICCA, Age-specific Incident Cases of ICCA, Stage-specific Incident Cases of ICCA, and Biomarker-specific Incident Cases of ICCA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Intrahepatic Cholangiocarcinoma (ICCA) Detailed Epidemiology Segmentation
• In 2017, a total of 10,177 patients were affected with ICCA in the 7MM.
• The United States contributes the largest share with 3,639 incident cases in 2017, acquiring near about 35.76% of the totals 7MM share. On the other hand, EU5 and Japan will account for 37.40% and 26.84% population share, respectively, by 2017.
• ICCA is more common in males as compared to females. In 2017, males contributed to 50.9% of all incident cases of ICCA in the US.
• OId age patients are at higher risk of developing ICCA. In the US, the age group 70–79 years contributed to 28% of the ICCA incident cases in 2017.
• ICCA is most commonly diagnosed in later stages of cancer. In 2017, 69% of the cases were diagnosed in stage III and stage IV in the US.
• Biomarkers such as VEGF overexpression, IDH1/IDH2 mutation, and FGFR translocations are most commonly seen in ICCA. They were found in 28%, 16%, and 15% of the ICCA cases in 2017.
• In EU5 countries, Italy contributed the largest share in ICCA incident cases, followed by Germany. In contrast, Spain accounted for the lowest share in ICCA incident cases.
• In 2017, the incident population of ICCA in Japan was 2,731.

Scope of the Report
• The report covers the descriptive overview of ICCA, explaining its signs and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of ICCA.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of ICCA, Gender-specific Incident Cases of ICCA, Age-specific Incident Cases of ICCA, Stage-specific Incident Cases of ICCA, and Biomarker-specific Incident Cases of ICCA.

Report Highlights
• 11-Year Forecast of ICCA
• 7MM Coverage
• Total Incident Cases of ICCA
• Gender-specific Incident Cases of ICCA
• Age-specific Incident Cases of ICCA
• Stage-specific Incident Cases of ICCA
• Biomarker-specific Incident Cases of ICCA

Key Questions Answered
• What are the disease risk, burdens, and unmet needs of ICCA?
• What is the historical ICCA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of ICCA at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to ICCA?
• Out of the above-mentioned countries, which country would have the highest incident population of ICCA during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The ICCA report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM ICCA epidemiology forecast.
• The ICCA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The ICCA epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030


1 Key Insights
2 Executive Summary of Intrahepatic Cholangiocarcinoma (ICCA)
3 Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology Overview at a Glance
3.1 Total Epidemiology Share (%) Distribution of ICCA in 2017
3.2 Total Epidemiology Share (%) Distribution of ICCA in 2030
4 Intrahepatic cholangiocarcinoma (ICCA): Disease Background and Overview
4.1 Introduction
4.2 Intrahepatic cholangiocarcinoma (ICCA)
4.3 Symptoms of ICCA
4.4 Traditional and new classifications of intrahepatic cholangiocarcinoma
4.5 Molecular pathogenesis of intrahepatic cholangiocarcinoma
4.6 Diagnosis of Intrahepatic CCA
4.6.1 Algorithm for the diagnosis of ICCA
4.6.2 Staging of Intrahepatic CCA (ICCA)
5 Epidemiology and Patient Population
5.1 Key Findings
5.2 Epidemiology Methodology
5.3 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM
6 United States Epidemiology
6.1 Assumptions and Rationale
6.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the United States
6.3 Gender-specific Incident Cases ICCA in the United States
6.4 Age-specific Incident Cases of ICCA in the United States
6.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United States
6.6 Biomarker-specific Incident Cases of ICCA in the United States
7 EU5 Epidemiology
7.1 Germany Epidemiology
7.1.1 Assumptions and Rationale
7.1.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Germany
7.1.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
7.1.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
7.1.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
7.1.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Germany
7.2 France Epidemiology
7.2.1 Assumptions and rationale
7.2.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in France
7.2.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
7.2.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
7.2.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
7.2.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in France
7.3 Italy Epidemiology
7.3.1 Assumptions and Rationale
7.3.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Italy
7.3.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
7.3.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
7.3.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
7.3.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Italy
7.4 Spain Epidemiology
7.4.1 Assumptions and Rationale
7.4.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Spain
7.4.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
7.4.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
7.4.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
7.4.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Spain
7.5 United Kingdom Epidemiology
7.5.1 Assumptions and Rationale
7.5.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the United Kingdom
7.5.3 Gender-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United Kingdom
7.5.4 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United Kingdom
7.5.5 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the UK
7.5.6 Biomarker-specific Incident Cases of Intrahepatic Cholangiocarcinoma in the United Kingdom
8 Japan Epidemiology
8.1 Assumptions and Rationale
8.2 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Japan
8.3 Gender-specific Incident Cases of ICCA in Japan
8.1 Age-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Japan
8.2 Stage-specific Incident Cases of Intrahepatic Cholangiocarcinoma in Japan
8.3 Biomarker-specific Incident Cases of ICCA in Japan
9 Appendix
9.1 Report Methodology
10 DelveInsight Capabilities
11 Disclaimer
12 About DelveInsight
Table 1 Summary of Intrahepatic Cholangiocarcinoma (ICCA), Epidemiology, and Key Events (2017–2030)
Table 2 Gross features of intrahepatic cholangiocarcinoma
Table 3 Classification of ICCA
Table 4 Molecular alterations in ICCA
Table 5 TNM and AJCC/ UICC Staging Systems for Intrahepatic Cholangiocarcinoma
Table 6 AJCC staging of intrahepatic cholangiocarcinoma: comparison of 7th and 8th editions
Table 7 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM (2017–2030)
Table 8 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the US (2017–2030)
Table 9 Gender-specific Incident Cases of ICCA in the US (2017–2030)
Table 10 Age-specific Incident Cases of ICCA in the US (2017–2030)
Table 11 Stage-specific Incident Cases of Intrahepatic CCA in the US (2017–2030)
Table 12 Biomarker-specific Incident Cases of ICCA in the US (2017–2030)
Table 13 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Germany (2017–2030)
Table 14 Gender-Specific Incident Cases of ICCA in Germany (2017–2030)
Table 15 Age-specific Incident Cases of ICCA in Germany (2017–2030)
Table 16 Stage-specific Incident Cases of Intrahepatic CCA in Germany (2017–2030)
Table 17 Biomarker-specific Incident Cases of ICCA in Germany (2017–2030)
Table 18 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in France (2017–2030)
Table 19 Gender-specific Incident Cases of ICCA in France (2017–2030)
Table 20 Age-specific Incident Cases of ICCA in France (2017–2030)
Table 21 Stage-specific Incident Cases of Intrahepatic CCA in France (2017–2030)
Table 22 Biomarker-specific Incident Cases of ICCA in France (2017–2030)
Table 23 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Italy (2017–2030)
Table 24 Gender-specific Incident Cases of ICCA in Italy (2017–2030)
Table 25 Age-specific Incident Cases of ICCA in Italy (2017–2030)
Table 26 Stage-specific Incident Cases of Intrahepatic CCA in Italy (2017–2030)
Table 27 Biomarker-specific Incident Cases of ICCA in Italy (2017–2030)
Table 28 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Spain (2017–2030)
Table 29 Gender-specific Incident Cases of ICCA in Spain (2017–2030)
Table 30 Age-specific Incident Cases of ICCA in Spain (2017–2030)
Table 31 Stage-specific Incident Cases of Intrahepatic CCA in Spain (2017–2030)
Table 32 Biomarker-specific Incident Cases of ICCA in Spain (2017–2030)
Table 33 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the UK (2017–2030)
Table 34 Gender-specific Incident Cases of CCA in the UK (2017–2030)
Table 35 Age-specific Incident Cases of ICCA in the UK (2017–2030)
Table 36 Stage-specific Incident Cases of Intrahepatic CCA in the UK (2017–2030)
Table 37 Biomarker-specific Incident Cases of ICCA in the UK (2017–2030)
Table 38 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Japan (2017–2030)
Table 39 Gender-specific Incident Cases of ICCA in Japan (2017–2030)
Table 40 Age-specific Incident Cases of ICCA in Japan (2017–2030)
Table 41 Stage-specific Incident Cases of Intrahepatic CCA in Japan (2017–2030)
Table 42 Biomarker-specific Incident Cases of ICCA in Japan (2017–2030)
Figure 1 Cholangiocarcinoma
Figure 2 Cholangiocarcinoma - anatomical classification
Figure 3 Gross features of intrahepatic cholangiocarcinoma
Figure 4 Symptoms of ICCA
Figure 5 Summary of key molecular alterations involved in ICCA carcinogenesis
Figure 6 Algorithm for management and diagnosis of intrahepatic cholangiocarcinoma
Figure 7 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the 7MM (2017–2030)
Figure 8 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the US (2017–2030)
Figure 9 Gender-specific Incident Cases of ICCA in the US (2017–2030)
Figure 10 Age-specific Incident Cases of ICCA in the US (2017–2030)
Figure 11 Stage-specific Incident Cases of Intrahepatic CCA in the US (2017–2030)
Figure 12 Biomarker-specific Incident Cases of ICCA in the US (2017–2030)
Figure 13 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Germany (2017–2030)
Figure 14 Gender-specific Incident Cases of ICCA in Germany (2017–2030)
Figure 15 Age-specific Incident Cases of ICCA in Germany (2017–2030)
Figure 16 Stage-specific Incident Cases of Intrahepatic CCA in Germany (2017–2030)
Figure 17 Biomarker-specific Incident Cases of ICCA in Germany (2017–2030)
Figure 18 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in France (2017–2030)
Figure 19 Gender-specific Incident Cases of ICCA in France (2017–2030)
Figure 20 Age-specific Incident Cases of ICCA in France (2017–2030)
Figure 21 Stage-specific Incident Cases of Intrahepatic ICCA in France (2017–2030)
Figure 22 Biomarker-specific Incident Cases of ICCA in France (2017–2030)
Figure 23 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Italy (2017–2030)
Figure 24 Gender-specific Incident Cases of ICCA in Italy (2017–2030)
Figure 25 Age-specific Incident Cases of ICCA in Italy (2017–2030)
Figure 26 Stage-specific Incident Cases of Intrahepatic CCA in Italy (2017–2030)
Figure 27 Biomarker-specific Incident Cases of ICCA in Italy (2017–2030)
Figure 28 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Spain (2017–2030)
Figure 29 Gender-specific Incident Cases of ICCA in Spain (2017–2030)
Figure 30 Age-specific Incident Cases of ICCA in Spain (2017–2030)
Figure 31 Stage-specific Incident Cases of Intrahepatic CCA in Spain (2017–2030)
Figure 32 Biomarker-specific Incident Cases of ICCA in Spain (2017–2030)
Figure 33 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in the UK (2017–2030)
Figure 34 Gender-specific Incident Cases of CCA in the UK (2017–2030)
Figure 35 Age-specific Incident Cases of ICCA in the UK (2017–2030)
Figure 36 Stage-specific Incident Cases of Intrahepatic CCA in the UK (2017–2030)
Figure 37 Biomarker-specific Incident Cases of ICCA in the UK (2017–2030)
Figure 38 Total Incident Cases of Intrahepatic Cholangiocarcinoma (ICCA) in Japan (2017–2030)
Figure 39 Gender-specific Incident Cases of ICCA in Japan (2017–2030)
Figure 40 Age-specific Incident Cases of ICCA in Japan (2017–2030)
Figure 41 Stage-specific Incident Cases of Intrahepatic CCA in Japan (2017–2030)
Figure 42 Biomarker-specific Incident Cases of ICCA in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook